Literature DB >> 29550458

Circulating bone morphogenetic protein-9 levels are associated with hypertension and insulin resistance in humans.

Hong Huang1, Wei Wang2, Gangyi Yang2, Yu Zhang1, Xiaoqiang Li3, Hua Liu4, Lin Zhang5, Hongting Zheng6, Ling Li7.   

Abstract

It has been demonstrated that bone morphogenetic protein-9 (BMP-9) may have an important role in vascular development and stability. However, the association of circulating BMP-9 with essential hypertension (HTN) has not been established in humans. The objective of this study is to observe the changes of circulating BMP-9 levels in patients with HTN and to investigate the association of circulation BMP-9 and insulin resistance (IR) in a cross-sectional study. Two hundred twenty-five individuals, including 132 patients with hypertension, and 93 healthy controls, were included in the present study. Circulating BMP-9 concentrations were measured with an ELISA kit. The association of circulating BMP-9 with other parameters was analyzed. When compared with healthy subjects, circulating BMP-9 concentrations were markedly lower in HTN patients (46.20 [31.85-62.80] vs. 77.21 [39.33-189.15], P < .01) and correlated negatively with blood pressure and the homeostasis model assessment of insulin resistance (P < .05 or P < .01). Decreasing levels of BMP-9 were independently and markedly related to HTN. In a multiple linear regression analysis, only systolic blood pressure and free fatty acid concentrations were independently associated with circulating BMP-9. Our findings suggest that BMP-9 may be a serum biomarker for HTN and IR.
Copyright © 2018 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone morphogenetic protein; cross-sectional study; hypertension; insulin resistance

Year:  2018        PMID: 29550458     DOI: 10.1016/j.jash.2018.02.007

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  2 in total

Review 1.  New insights into BMP9 signaling in liver diseases.

Authors:  Qian-Qian Jiang; Bei-Bei Liu; Ke-Shu Xu
Journal:  Mol Cell Biochem       Date:  2021-05-21       Impact factor: 3.396

2.  Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool.

Authors:  Carlos Ernesto Fernández-García; Stephania C Isaza; Esther Rey; Patricia Marañón; Rocío Gallego-Durán; Rocío Montero-Vallejo; Javier Rodríguez de Cía; Javier Ampuero; Manuel Romero-Gómez; Carmelo García-Monzón; Águeda González-Rodríguez
Journal:  Biomark Res       Date:  2022-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.